Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.12.017
Background: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. Methods: Single center retrospective designed observational study conducted in Ankara City Hospital. Patients who were hospitalized between March 15, 2020 and June 1, 2020 in COVID-19 inpatient clinics with laboratory confirmed diagnosis of COVID-19 were included in the study. An inverse probability of treatment weighting (IPTW) for multiple treatment groups approach was used to balance the differences in several variables on admission. Results: Among 2441 patients hospitalized with diagnosis of COVID-19 during the study period, 824 were eligible for the analysis. Median age of patients was 42 (18−93 years). Among all, 347 (43.2%) of the patients had mild disease, 470 (56.8%) had pneumonia. Propensity scores ranged from 0.1841 to 0.9381 in the HCQ group, from 0.03643 to 0.29885 in the favipiravir group, and from 0.03542 to 0.56184 in the HCQ plus favipiravir group. After IPTW for multiple treatment groups was applied, all the covariates in the planned propensity score had weighted standardized effect sizes below 10% which were ranged from 0.005 to 0.092. Multivariate analysis of treatment effect (adjusted effect of treatment) was indicated that there is no statistically significant difference between HCQ, favipiravir, and HCQ plus favipiravir treatment. After using combination of SMOTE and Bootstrap resampling approach, we found no statistically significant difference between HCQ and HCQ plus favipiravir groups in terms of ICU admission. However, compared with the HCQ group, ICU admission rate was statistically significantly higher in the favipiravir group. We obtained the similar results after the sensitivity analysis.
Author contributions Concept and design of the study: RG, IH, BK, EA, AKK, FE. Data collection: IH, BK, AA, AKK, FE, OK, YTT, ZB, FMG, HNA. Data analysis: RG, IH, IA, AB, BC, S İ, DE, SA, MC, HB. Interpretation of the data: RG, IH, BK, EA, HH, HK, OK, FE. Drafting the manuscript: RG, IH, TB, BK. Critical revision of the manuscript: IH, BK, AA, EA, SI, DE. All authors approved the final version of the manuscript.
Ethical approval The study was approved by the Turkish Ministry of Health and ethics board of Ankara City Hospital (No: E1-20-764).
Conflict of interest None to declare.
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.099
Borba, Val, Sampaio, Alexandre, Melo et al., Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial, JAMA Netw Open, doi:10.5582/bst.2020.01047
Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.tmaid.2020.101791
Catteau, Dauby, Montourcy, Bottieau, Hautekiet et al., Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants, Int J Antimicrob Agents, doi:10.1016/j.ijid.2020.06.099
Covid-, Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: findings from the observational multicentre Italian CORIST study, Eur J Intern Med, doi:10.1016/j.ijantimicag.2020.106144
Doi, Hibino, Hase, Yamamoto, Kasamatsu et al., A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19, Antimicrob Agents Chemother, doi:10.1016/j.ejim.2020.08.019
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, doi:10.1128/AAC.01897-20
Huang, Tang, Pang, Li, Ma et al., Treating COVID-19 with chloroquine, J Mol Cell Biol, doi:10.1136/bmj.m2328
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial, Clin Infect Dis, doi:10.1093/cid/ciaa1176
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis, Travel Med Infect Dis, doi:10.1093/jmcb/mjaa014
Lumley, survey: analysis of complex survey samples, R package version
Mitjà, Corbacho-Monné, Ubals, Tebe, Ñafiel et al., Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial, Clin Infect Dis, doi:10.1093/cid/ciaa1176
Ridgeway, Mccaffrey, Morral, Griffin, Burgette et al., Twang: Toolkit for weighting and analysis of nonequivalent groups
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA, doi:10.1093/cid/ciaa1009
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ, doi:10.1001/jamanetworkopen.2020.8857
Walter, Practical propensity score methods using R
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1001/jama.2020.8630
Yee, VGAM: Vector Generalized Linear and Additive Models